

# HARS antibody - N-terminal region

Rabbit Polyclonal Antibody Catalog # AI14656

#### **Product Information**

Application WB Primary Accession P12081

Other Accession NM 002109, NP 002100

**Reactivity** Human, Mouse, Rat, Rabbit, Zebrafish, Pig, Dog, Guinea Pig, Horse, Bovine

Predicted Human, Mouse, Rat, Rabbit, Zebrafish, Chicken, Dog

Host Rabbit
Clonality Polyclonal
Calculated MW 57411

#### **Additional Information**

Gene ID 3035

Alias Symbol FLJ20491, HRS, USH3B

Other Names Histidine--tRNA ligase, cytoplasmic, 6.1.1.21, Histidyl-tRNA synthetase, HisRS,

HARS, HRS

Format Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium

azide and 2% sucrose.

**Reconstitution & Storage** Add 50 ul of distilled water. Final anti-HARS antibody concentration is 1 mg/ml

in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C.

Avoid repeat freeze-thaw cycles.

**Precautions** HARS antibody - N-terminal region is for research use only and not for use in

diagnostic or therapeutic procedures.

#### **Protein Information**

Name HARS1 ( HGNC:4816)

**Synonyms** HARS, HRS

**Function** Catalyzes the ATP-dependent ligation of histidine to the 3'- end of its cognate

tRNA, via the formation of an aminoacyl-adenylate intermediate (His-AMP) (PubMed: 29235198). Plays a role in axon guidance (PubMed: 26072516).


Cellular Location Cytoplasm {ECO:0000250 | UniProtKB:F1Q5D5}.

**Tissue Location** Brain, heart, liver and kidney.

### References

Raben N.,et al.Nucleic Acids Res. 20:1075-1081(1992). Tsui F.W.L.,et al.Nucleic Acids Res. 15:3349-3367(1987). Ota T.,et al.Nat. Genet. 36:40-45(2004). Totoki Y.,et al.Submitted (JUL-2006) to the EMBL/GenBank/DDBJ databases. Schmutz J.,et al.Nature 431:268-274(2004).

## **Images**



WB Suggested Anti-HARS Antibody Titration: 1.0  $\mu$ g/ml Positive Control: 293T Whole CellHARS is supported by BioGPS gene expression data to be expressed in HEK293T

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.